Grace Therapeutics Inc (GRCE)
3.125
+0.02
(+0.81%)
USD |
NASDAQ |
Oct 31, 16:00
3.15
+0.02
(+0.80%)
After-Hours: 20:00
Grace Therapeutics EPS Diluted (Quarterly): -0.24 for June 30, 2024
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -0.24 |
| March 31, 2024 | -0.4297 |
| December 31, 2023 | -0.3249 |
| September 30, 2023 | -0.43 |
| June 30, 2023 | -0.54 |
| March 31, 2023 | -3.91 |
| December 31, 2022 | -0.52 |
| September 30, 2022 | -0.66 |
| June 30, 2022 | -0.61 |
| March 31, 2022 | -0.5289 |
| December 31, 2021 | -0.54 |
| September 30, 2021 | 0.18 |
| June 30, 2021 | -0.72 |
| March 31, 2021 | -1.301 |
| December 31, 2020 | -1.56 |
| September 30, 2020 | -3.12 |
| June 30, 2020 | -2.40 |
| March 31, 2020 | 10.08 |
| December 31, 2019 | -6.72 |
| September 30, 2019 | -12.00 |
| June 30, 2019 | -5.28 |
| March 31, 2019 | -8.609 |
| December 31, 2018 | -2.467 |
| September 30, 2018 | -23.03 |
| June 30, 2018 | -8.394 |
| Date | Value |
|---|---|
| March 31, 2018 | -11.36 |
| December 31, 2017 | -15.27 |
| September 30, 2017 | -11.99 |
| June 30, 2017 | -7.012 |
| November 30, 2016 | -7.860 |
| August 31, 2016 | -8.067 |
| May 31, 2016 | -10.67 |
| February 29, 2016 | -6.180 |
| November 30, 2015 | -7.539 |
| August 31, 2015 | -4.350 |
| May 31, 2015 | -3.476 |
| February 28, 2015 | -8.653 |
| November 30, 2014 | 11.73 |
| August 31, 2014 | -13.24 |
| May 31, 2014 | 4.424 |
| February 28, 2014 | -5.279 |
| November 30, 2013 | -22.61 |
| August 31, 2013 | -18.21 |
| May 31, 2013 | -13.97 |
| February 28, 2013 | -8.373 |
| November 30, 2012 | -9.664 |
| August 31, 2012 | -9.667 |
| May 31, 2012 | -9.316 |
| February 29, 2012 | -11.09 |
| November 30, 2011 | -13.95 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-6.72
Minimum
Dec 2019
10.08
Maximum
Mar 2020
-0.7523
Average
-0.54
Median
Dec 2021
EPS Diluted (Quarterly) Benchmarks
| Aurinia Pharmaceuticals Inc | 0.01 |
| Edesa Biotech Inc | -0.52 |
| Lexaria Bioscience Corp | -0.13 |
| Xenon Pharmaceuticals Inc | -0.75 |
| ESSA Pharma Inc | -0.16 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.617M |
| Total Expenses (Quarterly) | 4.963M |
| Enterprise Value | 12.28M |
| Earnings Yield | -45.59% |
| Normalized Earnings Yield | -159.59 |